Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on August 30, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print August 30, 2007, doi: 10.1161/ATVBAHA.107.151894
A more recent version of this article appeared on November 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/11/2420    most recent
ATVBAHA.107.151894v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lichtenstein, L.
Right arrow Articles by Kersten, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lichtenstein, L.
Right arrow Articles by Kersten, S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Nucleotide
*Protein*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL

Submitted on May 4, 2007
Accepted on August 8, 2007

Angptl4 Upregulates Cholesterol Synthesis in Liver via Inhibition of LPL- and HL-Dependent Hepatic Cholesterol Uptake

Laeticia Lichtenstein ; Jimmy F.P. Berbée ; Susan J. van Dijk ; Ko Willems van Dijk ; André Bensadoun ; Ido P. Kema ; Peter J. Voshol ; Michael Müller ; Patrick C.N. Rensen ; and Sander Kersten *

From the Nutrigenomics Consortium (L.L., K.W.v.D., M.M., S.K.), TI Food and Nutrition, Wageningen, the Netherlands; Nutrition, Metabolism, and Genomics group (L.L., S.J.v.D., M.M., S.K.), Wageningen University, Wageningen, the Netherlands; the Departments of General Internal Medicine (J.F.P.B., K.W.v.D., P.C.N.R.), Endocrinology and Metabolic Diseases (J.F.P.B., P.J.V., P.C.N.R.), and Human Genetics (K.W.v.D.), Leiden University Medical Center, Leiden, the Netherlands; the Division of Nutritional Sciences (A.B.), Cornell University, Ithaca, NY; and Pathology and Laboratory Medicine (I.P.K.), University Medical Center Groningen, Groningen, the Netherlands.

* To whom correspondence should be addressed. E-mail: sander.kersten{at}wur.nl.

Background—Dysregulation of plasma lipoprotein levels may increase the risk for atherosclerosis. Recently, angiopoietin-like protein 4, also known as fasting-induced adipose factor Fiaf, was uncovered as a novel modulator of plasma lipoprotein metabolism. Here we take advantage of the fasting-dependent phenotype of Angptl4-transgenic (Angptl4-Tg) mice to better characterize the metabolic function of Angptl4.

Methods and Results—In 24-hour fasted mice, Angptl4 overexpression increased plasma triglycerides (TG) by 24-fold, which was attributable to elevated VLDL-, IDL/LDL- and HDL-TG content. Angptl4 overexpression decreased post-heparin LPL activity by stimulating conversion of endothelial-bound LPL dimers to circulating LPL monomers. In fasted but not fed state, Angptl4 overexpression severely impaired LPL-dependent plasma TG and cholesteryl ester clearance and subsequent uptake of fatty acids and cholesterol into tissues. Consequently, hepatic cholesterol content was significantly decreased, leading to universal upregulation of cholesterol and fatty acid synthesis pathways and increased rate of cholesterol synthesis.

Conclusions—The hypertriglyceridemic effect of Angptl4 is attributable to inhibition of LPL-dependent VLDL lipolysis by converting LPL dimers to monomers, and Angptl4 upregulates cholesterol synthesis in liver secondary to inhibition of LPL- and HL-dependent hepatic cholesterol uptake.